SCHEMBL3759707

SCHEMBL3759707

COc1cc(N(C)C)ccc1Nc1nccc(-c2c(Cl)nc3sccn23)n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MKNK2 Q9HBH9 8/20 0.46
MKNK1 Q9BUB5 5/20 0.46
FLT3 P36888 4/20 0.46
KDR P35968 5/20 0.45
LCK P06239 4/20 0.45
CSF1R P07333 4/20 0.45
IGF1R P08069 3/20 0.45
MAP4K4 O95819 3/20 0.45
RET P07949 3/20 0.45
FLT1 P17948 3/20 0.45
MAP4K2 Q12851 3/20 0.45
STK3 Q13188 3/20 0.45
TAOK1 Q7L7X3 3/20 0.45
MAP4K5 Q9Y4K4 3/20 0.45
PRKD3 O94806 2/20 0.45
FYN P06241 2/20 0.45
MET P08581 2/20 0.45
ROS1 P08922 2/20 0.45
AURKB Q96GD4 2/20 0.45
PAK4 O96013 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3758950 0.85 MAPK8 (0.50) KDRLCKCSF1RIGF1RMAP4K4
SCHEMBL3765209 0.83 CDK2 (0.52) MKNK2MKNK1FLT3IGF1REGFR
SCHEMBL3769704 0.83 PLK1 (0.52) IGF1RROS1EGFR
SCHEMBL3765117 0.79 KDR (0.57) FLT3KDRLCKCSF1RIGF1R
SCHEMBL3767858 0.77 KDR (0.46) KDRLCKCSF1RIGF1RMAP4K4
SCHEMBL3765186 0.76 KDR (0.52) KDRLCKCSF1RIGF1RMAP4K4
SCHEMBL3769717 0.75 KDR (0.46) KDRLCKCSF1RIGF1RMAP4K4
SCHEMBL3760282 0.75 CSF1R (0.47) KDRLCKCSF1RIGF1RMAP4K4
SCHEMBL12996178 0.75 KDR (0.46) FLT3KDRLCKCSF1RIGF1R
SCHEMBL3756635 0.74 EGFR (0.53) IGF1REGFRERBB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2435436-B1 PYRIMIDINE INHIBITORS OF KINASE ACTIVITY ABBVIE INC (US) 2014-07-30 EP disclosed
EP-2435435-B1 PYRIMIDINE INHIBITORS OF KINASE ACTIVITY ABBVIE INC (US) 2014-01-29 EP disclosed
US-8536180-B2 Pyrimidine inhibitors of kinase activity ABBVIE INC. (US) 2013-09-17 US disclosed
US-8354422-B2 Pyrimidine inhibitors of kinase activity ABBOTT LABORATORIES INC. (US) 2013-01-15 US disclosed
US-20100305118-A1 PYRIMIDINE INHIBITORS OF KINASE ACTIVITY ABBOTT LABORATORIES (US) 2010-12-02 US disclosed
US-20100305126-A1 Pyrimidine Inhibitors of Kinase Activity ABBOTT LABORATORIES (US) 2010-12-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305126-A1 Pyrimidine Inhibitors of Kinase Activity IGF1R, CDK2, TK1 MKNK2 290/4885MKNK1 337/4885FLT3 208/4885
US-20100305118-A1 PYRIMIDINE INHIBITORS OF KINASE ACTIVITY IGF1R, TK1, CDK2 MKNK2 214/4885MKNK1 198/4885FLT3 432/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.